Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
An efficient CRISPR/Cas9 knock-in system to restore full-length dystrophin
EF 2018-19
Résumé
Duchenne Muscular Dystrophy (DMD) is a neuromuscular disease causing progressive muscle loss. At 10 years old, patients lose independent movement, with fatal respiratory or cardiac complications in their mid to late teens. Mutations in the gene for dystrophin, a protein essential to muscle integrity, cause DMD. There is no cure, with current and proposed treatments lacking effectiveness or feasibility.
CRISPR/Cas9 is a gene editing protein that could fix dystrophin, as it can be programmed to cut DNA at a specific spot, opening an editing window during DNA repair. 70% of DMD patients have lost critical DNA in their dystrophin gene. Therefore, this project aims to reinsert the DNA precisely where it was lost. However, insertion efficiency is low, and worse in non-dividing cells like muscle. Recent work shows a DNA repair system called homologous-mediated end joining (HMEJ) is highly efficient for insertions in non-dividing cells, reaching rates of 58% in the neurons of live mice.
HMEJ works by attaching additional DNA to the lost dystrophin DNA that will be inserted. This newly added DNA is identical to the area in the genome where the insertion will occur. Insertion efficiency is significantly increased because of the matching sequences. After CRISPR/Cas9 cuts the genome at the desired spot, the insertion process takes place to repair the dystrophin gene. Muscles should then produce fully functional dystrophin, preventing degradation. The threshold to cure DMD is surprisingly low, requiring only 15% of normal dystrophin levels. Today, human gene editing is prohibited. But should that change, and this gene therapy can restore dystrophin, most DMD patients would have a future to look toward.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
411288
Name
Rok Matthew
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
An efficient CRISPR/Cas9 knock-in system to restore full-length dystrophin
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aav Vector; Crispr/Cas9; Duchenne Muscular Dystrophy; Dystrophin Restoration; Gene Editing; Gene Therapy; Homologous-Mediated End Joining; Knock-In; Muscle
Abstract
Duchenne Muscular Dystrophy (DMD) is a neuromuscular disease causing progressive muscle loss. At 10 years old, patients lose independent movement, with fatal respiratory or cardiac complications in their mid to late teens. Mutations in the gene for dystrophin, a protein essential to muscle integrity, cause DMD. There is no cure, with current and proposed treatments lacking effectiveness or feasibility.
CRISPR/Cas9 is a gene editing protein that could fix dystrophin, as it can be programmed to cut DNA at a specific spot, opening an editing window during DNA repair. 70% of DMD patients have lost critical DNA in their dystrophin gene. Therefore, this project aims to reinsert the DNA precisely where it was lost. However, insertion efficiency is low, and worse in non-dividing cells like muscle. Recent work shows a DNA repair system called homologous-mediated end joining (HMEJ) is highly efficient for insertions in non-dividing cells, reaching rates of 58% in the neurons of live mice.
HMEJ works by attaching additional DNA to the lost dystrophin DNA that will be inserted. This newly added DNA is identical to the area in the genome where the insertion will occur. Insertion efficiency is significantly increased because of the matching sequences. After CRISPR/Cas9 cuts the genome at the desired spot, the insertion process takes place to repair the dystrophin gene. Muscles should then produce fully functional dystrophin, preventing degradation. The threshold to cure DMD is surprisingly low, requiring only 15% of normal dystrophin levels. Today, human gene editing is prohibited. But should that change, and this gene therapy can restore dystrophin, most DMD patients would have a future to look toward.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rok, Matthew
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~